

GERIATRIC MEDICINE AND ELDERLY CARE

Lecture Notes



Claire G. Nicholl
K. Jane Wilson
Shaun D'Souza

Ninth Edition



WILEY Blackwell

Geriatric Medicine and Elderly Care

Lecture Notes

Geriatric Medicine and Elderly Care

Lecture Notes

Claire G. Nicholl

MB FRCP
Consultant Geriatrician (Emerita)

K. Jane Wilson

MB FRCP
Consultant Geriatrician

Shaun D'Souza

MB MRCP
Consultant Geriatrician

All of:
Department of Medicine for the Elderly
Addenbrooke's Hospital
Cambridge University Hospitals NHS Foundation Trust
Cambridge, UK

Ninth Edition

WILEY Blackwell

This ninth edition first published in 2025
© 2025 John Wiley & Sons Ltd.

Edition History

[8e, 2012, by Wiley-Blackwell]

All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Claire G. Nicholl, K. Jane Wilson, and Shaun D'Souza to be identified as the authors of this work has been asserted in accordance with the law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
New Era House, 8 Oldlands Way, Bognor Regis, West Sussex, PO22 9NQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products, visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific methods, diagnoses, or treatments by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. The fact that an organisation, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organisation, website, or product may provide or recommendations it may make. Further, readers should be aware that the websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor the authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloguing-in-Publication Data applied for

Paperback ISBN: 9781119627593

Cover Design: Wiley

Cover Image: © Francesca DB Photography

Set in 8.5/11pt Utopia by Straive, Pondicherry, India

Contents

- Preface, vi
Note about the cover, vii
Note about doses, viii
Acknowledgments, ix
Abbreviations, x
About the companion website, xvi
- 1 Global ageing, 1
2 Health and social care in the UK, 20
3 The science of ageing, 40
4 Core geriatric medicine, 49
5 Drugs and prescribing, 61
6 Surgery, 68
7 Neurology, 75
8 Old-age psychiatry, 89
9 Stroke, 111
- 10 Musculoskeletal, 126
11 Falls and immobility, 144
12 Cardiovascular medicine, 161
13 Respiratory medicine, 178
14 Gastroenterology, 191
15 Genitourinary medicine, 211
16 Homeostasis and endocrinology, 229
17 Haematology, 237
18 Oncogeriatrics, 251
19 Dermatology, 258
20 Eyes and ENT, 267
21 Legal and ethical aspects, 280
22 Palliative care, 290
- Index, 298

Preface

The ninth edition was commissioned before COVID-19, but the pandemic and its aftermath diverted attention from book writing, and the landscape of medicine has changed since the previous edition in 2012. Much of the text has been completely rewritten to reflect this.

Whatever branch of medicine you are studying or working in, with a few exceptions such as obstetrics or paediatrics, most of your patients will be older, or very old. Apart from Africa, this is now true across the world. Geriatricians have always promoted treating a person's 'biological age' rather than their 'chronological age', but this was difficult to define. The concept of frailty and simple ways to assess it are making this a reality. Outcomes across a range of specialties are linked to frailty rather than age, and older people who are likely to benefit are getting better access to new drugs and surgical procedures. All 21st century doctors need a solid grounding in geriatric medicine to be comfortable treating the majority of the patients they will see.

The biggest change for UK undergraduates is the upcoming Medical Licensing Assessment. Some medical schools still teach a 'geriatrics-light' version of the medical curriculum, but the General Medical Council content map focuses on topics that doctors are likely to encounter during the UK Foundation Programme. This obviously includes medicine that is relevant to older people, the biggest users of the health service.

The British Geriatrics Society published an updated curriculum for undergraduates in 2023, and this book covers this as well as the current European version. Global aspects of ageing are explained, and there is some detail on the organisation and delivery of health care in the UK. This can be difficult for students to grasp and will be particularly helpful for overseas-trained doctors taking the Professional and Linguistic Assessments Board (PLAB) examinations to work here. With increasing differences across the four nations, most detail is given about England, but the main differences are highlighted. The content will also provide a useful starting point for trainees revising for their Specialty Certificate Examination.

When so much information is instantly available online, is there still a place for textbooks? We believe so! The clue is the amount of information. Consider a well-defined topic such as 'Parkinson's disease' (PD). The National Institute for Health and Care Excellence (NICE) website currently lists 18 'products' about PD, with hundreds of pages, dating back to 2003. NICE Clinical Knowledge Summaries are shorter but also run to tens of pages, require multiple clicks to navigate, and sometimes give different advice to NICE guidelines. Then there are multiple 'best practice' sites, specialist society guidelines and finally the vast resource of primary literature. The advantage of a book is that we have provided a synthesis of the most important points that are relevant to our clinical

practice and highlighted areas of controversy. Once you have a basic grasp of an area, exploring it online will be more rewarding.

This book, like the population, is a little fatter than its predecessors. This is the result of both more advances in medicine being offered to older people (there is a new chapter on geriatric oncology) and a decision to include more explanation in the text. For example, there is enough detail about bone metabolism to understand, rather than just memorise, the drugs for osteoporosis. Our approach to medicine that empowers patients, and values working with the multidisciplinary team is relevant to patients of any age with chronic disease. For simplicity, when describing the prevalence of disease, female sex is used when referring to those assigned female at birth.

A typical older patient is more complex than a younger patient because of the interaction between their unique long-life experience and various comorbidities. Therefore, geriatric medicine is the medicine of complexity – interesting, varied, and challenging. If you enjoy using clinical acumen, leading and working in a team, and thinking about what really matters to an individual patient rather than following guidelines, consider a career in geriatric medicine. In addition to their core inpatient and community work, geriatricians are in demand across a wide and expanding range of clinical areas, for example in orthopaedics, surgical liaison, acute assessment, falls and syncope and movement disorders.

Geriatricians provide a large proportion of the examiners for PACES, the Practical Assessment of Clinical Examination Skills examination for the Royal College of Physicians. They are often excellent teachers, successful as medical managers and there are numerous opportunities for basic, epidemiological, and clinical research. There are many options for working overseas. After retiring from full-time work, CN had an enjoyable and satisfying time working and teaching in Botswana and teaching the European geriatrics curriculum as a visiting professor at the University of Pavia in Italy.

For years, geriatricians may have felt a little overshadowed by their single-organ specialty colleagues. In a world where patients are told they must present a single problem in a consultation with their GP and guideline medicine prevails in hospitals, the value of a comprehensive but individualised approach is increasingly recognised by patients, families, and colleagues. This edition has reverted to its original name, *Lecture Notes in Geriatric Medicine*.

Claire G. Nicholl

K. Jane Wilson

Shaun D'Souza

Cambridge, October 2024

Note about the cover

Cover image by Francesca DB Photography.

Isabella Mastantuono with her first great-granddaughter, Sofia.

Isabella had a very prolonged hospital stay. Her medical team began to wonder if they should keep on with burdensome rounds of treatment,

striving to try to get her better. Isabella and her family had a very different perspective. Four months after her discharge, they sent the team this photograph of Isabella, who was doing well and especially enjoying spending time with Sofia.

Published with permission from Isabella, Sofia's parents, and Francesca.

Note about doses

We have given doses of common drugs to help with familiarity and have tried to ensure that there are no errors, but please always check with a primary source such as the BNF or product literature before prescribing.

Acknowledgments

Thanks to Dr Matthew Butler for his input to the cardiology chapter, Prof. Liz Warburton for her contribution to the stroke chapter and Dr James Tanner for providing images.

We would also like to thank Nigel, Jo, and Hettie for their patience and support.

Abbreviations

5-HT	5 hydroxytryptamine (serotonin)	AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, a receptor for glutamate
5-HT _{2A}	5-HT _{2A} receptor	AMP-K	adenosine monophosphate activated protein kinase
A&E	accident and emergency, usually now known as the emergency department	AMTS	abbreviated mental test score
AA	alcoholics anonymous	ANH	artificial nutrition and hydration
AA	attendance allowance	ANS	autonomic nervous system
AAA	abdominal aortic aneurysm	anti-CCP/ACPA	anticitrullinated peptide antibody
AADC	aromatic amino acid decarboxylase	AP	antero-posteriorly
AAFB	acid and alcohol fast bacilli	APOE	apolipoprotein E
AaPO ₂	alveolar-arterial oxygen tension difference	APP	amyloid precursor protein
AAV	adeno-associated virus	ARB	angiotensin receptor blocker
A β	amyloid beta-peptide	ARDS	acute respiratory distress syndrome
ABCDE	approach for resuscitation: airway, breathing, circulation, disability, exposure	ARIA	amyloid-related imaging abnormalities
ABG	arterial blood gas	ARNI	ARB/ neprilysin inhibitor combination e.g. valsartan/ sacubitril
ABL-1	tyrosine protein kinase proto-oncogene	AS	Alzheimer's society
ABPI	arterial brachial pressure index	AS	aortic stenosis
ACA	anterior cerebral artery	ASA	American Society of Anesthesiology
ACB	anticholinergic burden	ASM	anti-seizure medication, previously anti-epileptic drugs
ACE	angiotensin-converting enzyme	ATN	acute tubular necrosis
ACEi	ACE inhibitor	AV	atrioventricular
AChE	acetylcholinesterase	AVP	arginine vasopressin
AChEi	acetylcholinesterase inhibitor	AXR	abdominal X-ray
AChR	acetylcholine receptor	BACE	β -secretase enzyme that cleaves transmembrane APP
ACIS	anterior circulation ischaemic stroke	BAFTA	Birmingham atrial fibrillation treatment of the aged study
ACP	advanced care planning	BAME	Black, Asian and ethnic minorities
ACR	albumin : creatinine ratio	BC	breast cancer
ACS	acute coronary syndrome	BCC	basal-cell carcinoma
ACS	anterior circulation stroke (context essential)	BCE	before common era
ACS NSQIP	American College of Surgeons national surgical quality improvement program	BCG	bacille Calmette Guérin
ACTH	adrenocorticotrophic hormone	BD	twice a day
AD	advance decision	BiTEs	bispecific T cell engagers
AD	Alzheimer's disease	BMA	British Medical Association
ADH	antidiuretic hormone	BMD	bone mineral density
ADL	activities of daily living	BMI	body mass index
ADORE	drug trial of edaravone in ALS	BMJ	British Medical Journal
ADR	adverse drug reaction	BNF	British National Formulary
ADRT	advance decision to refuse treatment	BNP	brain natriuretic peptide
ADT	androgen deprivation therapy	BOO	bladder outflow obstruction
AEDs	anti-epileptic drugs, now known as ASMs, see below	BOOP	bronchiolitis obliterans organizing pneumonia
AF	atrial fibrillation	BP	blood pressure
AFO	ankle-foot orthosis	BPH	benign prostatic hyperplasia
AIDP	acute inflammatory demyelinating polyradiculoneuropathy	BPI	bactericidal/permeability-increasing protein fold gene
AIDS	acquired immune deficiency syndrome	BPL	below the poverty line (households in India)
AIHA	autoimmune haemolytic anaemia	BPPV	benign paroxysmal positional vertigo
AIP	acute interstitial pneumonia	BPSD	behavioural and psychological symptoms of dementia
AJGP	Australian Journal of General Practice	BRAF	a serine/threonine protein kinase proto-oncogene with a critical role in MAPK cell signalling pathway.
AKI	acute kidney injury	BRAN	questions to ask about a new drug - benefits, risks, alternatives, do nothing?
AKT	a serine/threonine protein kinase, also known as protein kinase B, PKB	BRCA	breast cancer genes 1 and 2 (also increase risk of other cancers including ovary, pancreas, prostate)
ALD	alcoholic liver disease	BTS	British Thoracic Society
ALL	acute lymphoblastic leukaemia	BZD	benzodiazepine
ALP	alkaline phosphatase	CAA	cerebral amyloid angiopathy
ALS	amyotrophic lateral sclerosis	CABG	coronary artery bypass graft
AMD	age-related macular degeneration		
AMHP	approved mental health practitioner		
AML	acute myeloid leukaemia		
AMP/ADP/ATP	adenosine mono di and triphosphate		

CAD	coronary artery disease	CSS	carotid sinus syndrome
CADASIL	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	CT	computerized tomography
CAG	cytosine, adenine, guanine triplet repeats found in high numbers in Huntington's	CTPA	computerized tomography pulmonary angiogram
CAGE	screen for problem alcohol use	CTZ	chemoreceptor trigger zone
CAM	confusion assessment method	CUH	Cambridge University Hospitals (Addenbrooke's)
CAP	community acquired pneumonia	CVA	cerebrovascular accident
CAPD	continuous ambulatory peritoneal dialysis	CVP	central venous pressure
CAR	chimeric antigen receptor	CVS	cardiovascular system
CASSR	council with adult social services responsibility	CVT	central venous thrombosis
CAT	COPD assessment test	CXR	chest X-ray
CAUTI	catheter-associated UTI	DA	dopamine
CBD	corticobasal degeneration	DAA	direct acting antiviral
CBT	cognitive behavioural therapy	DAME	acronym for causes of falls (drugs, ageing, medical and environmental causes - female preponderance)
CBTI	cognitive behavioural therapy for insomnia	DAMPs	damage-associated molecular patterns
CCK	cholecystokinin	DAN	diabetic autonomic neuropathy
CCL5	chemokine ligand 5	DAPT	dual antiplatelet therapy
CCP	cyclic citrullinated peptide	DAT	dopamine transporter
CCU	coronary care unit	DBS	deep brain stimulation
CDAD	Clostridioides difficile-associated diarrhoea	DBS	disclosure and barring service
CDK	cyclin dependent kinase	DC	direct current
CFH	complement factor H	DE	dementia (elderly) - in the context of care home provision
CFS	clinical frailty score (Rockwood)	DESH	disproportionately enlarged subarachnoid space hydrocephalus
CGA	comprehensive geriatric assessment	DFLE	disability-free life expectancy
CGM	continuous glucose monitoring	DGH	district general hospital
CHA ₂ DS ₂ -VASc	score for risk of stroke in atrial fibrillation	DHSC	Department of Health and Social Care
CHARM	candesartan in heart failure assessment of reduction in morbidity and mortality study	DI	diabetes insipidus
CHART	continuous hyperfractionated accelerated ratdiortherapy	DIC	disseminated intravascular coagulation
CHC	continuing healthcare funding	DIP	distal interphalangeal
CHF	chronic heart failure	DLB	dementia with Lewy bodies
CI	confidence interval	DLCO	diffusing capacity for carbon monoxide
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy	DLUHC	Department for Levelling Up, Housing and Communities
CIWA	clinical institute withdrawal assessment - alcohol	DM	dermatomyositis
CK	creatin kinase	DM	diabetes mellitus
CKD	chronic kidney disease	DMARD	disease-modifying anti-rheumatic drug
CKM	conservative kidney management	DMT1	divalent metal transporter1
CK-MB	creatin kinase with muscle and brain subunits	DNA	deoxyribonucleic acid
CKS	clinical knowledge summary	DNACPR	do not attempt cardiopulmonary resuscitation
CLL	chronic lymphocytic leukaemia	DOAC	direct oral anticoagulant
CMA	chaperone-mediated autophagy	DOLS	deprivation of liberty safeguards
CMC	carpomtometocarpal	DORA	dual orexin receptor antagonists
CML	chronic myeloid leukaemia	DPLD	diffuse parenchymal lung disease
CNS	central nervous system	DPP	dipeptidyl peptidase
CO	carbon monoxide	DRD	Daratumumab + Revlimid (lenalidomide) + dexamethasone, an immunotherapy regimen for myeloma
CO ₂	carbon dioxide	DRE	digital rectal examination, sometimes abbreviated as PR (per rectum) which is also a route for drug administration
COHb	carboxyhaemoglobin	DSPN	diabetic sensorimotor polyneuropathy
COMT	catechol-O-methyltransferase	DVLA	Driver and Vehicle Licensing Authority
COP	cryptogenic organizing pneumonia	DVT	deep vein thrombosis
COPD	chronic obstructive pulmonary disease	DWI	diffusion weighted imaging (MRI)
COX-2	cyclo-oxygenase-2	DXA	dual-energy X-ray absorptiometry
CPAP	continuous positive airways pressure	E&W	England and Wales
CPN	community psychiatric nurse	ECG	electrocardiogram
CPPD	calcium pyrophosphate deposition disease	ECMO	extracorporeal membrane oxygenation
CPR	cardiopulmonary resuscitation	ECOG	Eastern Cooperative Oncology Group
CQC	Care Quality Commission	ECT	electroconvulsive therapy
CREST	acronym for calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia	ED	emergency department
CRHT	crisis resolution and home treatment team	EEG	electroencephalogram/graphy
CRP	C-reactive protein	eGFR	estimated glomerular filtration rate
CRT	conformal radiotherapy	EGFR	epidermal growth factor receptor
CRT-P	cardiac resynchronisation therapy - pacemaker	EuGMS	European Geriatric Medicine Society
CSF	cerebrospinal fluid	EIBC	early invasive breast cancer
CSM	carotid sinus massage		

ELISA	enzyme-linked immunosorbent assay	GSK	a pharma company, previously GlaxoSmith Kline
EMA	endomysial antibodies	GSM	genitourinary syndrome of menopause (new term for vulvovaginal atrophy)
EMG	electromyogram/electromyography	GTN	glyceryl trinitrate
ENT	ear, nose and throat	GU	genitourinary tract
EOFAD	early-onset familial Alzheimer's disease	GWAS	genome-wide association study
EPO	erythropoietin	h	hour
ER	(o)estrogen receptor	HALE	health-adjusted life expectancy
ER	endoplasmic reticulum	HASBLED	score for predicting bleeding risk of anticoagulation for AF, superseded by ORBIT
ERAD	endoplasmic reticulum-associated degradation	HCM	hypertrophic cardiomyopathy
ERCP	endoscopic retrograde cholangiopancreatography	HDU	high dependency unit
ESC	European Society of Cardiology	HPC	haemopoietic stem cell
ESKD	end stage kidney disease	HSC	haemopoietic stem cell
ESR	erythrocyte sedimentation rate	HER2	human epidermal growth factor receptor 2
ET	essential tremor	HERMES	outcomes of thrombectomy : highly effective reperfusion evaluated in multiple endovascular stroke trials
ET	essential thrombocythaemia		
EU	European Union		
EVAR	endovascular aneurysm repair		
EWGSOP2	European Working Group on Sarcopenia in Older People 2	HFE	high iron (Fe)/ human homeostatic iron regulator protein/ gene (mutations cause haemochromatosis)
FaME programme	fitness and mobility exercise programme	HFmrEF	heart failure with mildly reduced ejection fraction
FAST	face, arms, speech, time, score for stroke	HFpEF	heart failure with preserved ejection fraction
FBC	full blood count	HFREF	heart failure with reduced ejection fraction
FDA	Food and Drug Administration (US)	HHS	hyperosmolar hyperglycaemic syndrome
FDG	fluorodeoxyglucose	HINTS test	head impulse, nystagmus, test of skew test in vertigo
FEV1	forced expiratory volume in 1 s	HIV	human immunodeficiency virus
FGFR	fibroblast growth factor receptor	HL	Hodgkin's lymphoma
FIMDT	feeding issues multidisciplinary team	HLA	human leucocyte antigen
FIT	faecal immunochemical test	HLE	healthy life expectancy
FLAIR	fluid-attenuated inversion recovery, MRI sequence that shows grey matter as bright and CSF as dark	HLY	health-adjusted life expectancy
FNC	NHS funded nursing care	HMRN	Haematological Malignancy Research Network
FOCUS	fluoxetine on functional outcomes after acute stroke trial	HOOF	home oxygen order form
		HPC	haematopoietic stem cell
FOXO	forkhead box O: transcription factors with key roles in insulin signalling and ageing	HPV	human papilloma virus
		HRCT	high resolution computerized tomography scan
FRAX	fracture risk tool advocated by NOGG and NICE	HRT	hormone replacement therapy
FRIDS	falls-risk increasing drugs	HSC	haematopoietic stem cells
FRS	family research survey	HSMN	hereditary motor and sensory neuropathy
FSH	follicle stimulating hormone	HSV	Herpes simplex virus
FTD	frontotemporal dementia	HUT	head-up tilt
FTLD	frontotemporal lobar degeneration	HWB	health and wellbeing board
FUS	focused ultrasound	I131	iodine-131
FVC	forced vital capacity	IA	intraarticular
GABA	gamma-aminobutyric acid	IADL	instrumental activities of daily living
GARS	glycyl-tRNA synthetase	IBD	inflammatory bowel disease
GBS	Guillain-Barré syndrome	IBM	inclusion body myositis
GCA	giant-cell arteritis	IBS	irritable bowel syndrome
GCS	Glasgow coma score	IC	intermediate care
G-CSF	granulocyte colony stimulating factor	ICA	internal carotid artery
GDNF	glial cell-line derived nerve growth factor	ICB	integrated care board
GDP	gross domestic product	ICD	implantable cardioverter-defibrillator
GDS	geriatric depression score	ICH	intracerebral haemorrhage
GFR	glomerular filtration rate	ICP	intracranial pressure
GH	growth hormone	ICP	integrated care partnership
GI	gastrointestinal	ICS	inhaled corticosteroids
GIP	glucose-dependent insulinotropic polypeptide	ICS	integrated care system
GLP-1	glucagon-like peptide 1	ICU	intensive care unit
GLUT4	glucose transporter - a rate-limiting step in insulin-stimulated glucose uptake in muscle and adipocytes	IDA	iron deficiency anaemia
		IE	infective endocarditis
GMC	General Medical Council	Ig G, M, A, D and E	immunoglobulin classes
GnRH	gonadotrophin releasing hormone	IGF-1	insulin-like growth factor 1
GORD	gastro-oesophageal reflux disease	IHD	ischaemic heart disease
GP	general practitioner	IL	interleukin
GPCOG	general practice cognitive screening test for dementia	ILD	interstitial lung disease
		IM	intramuscular
GRACE	global registry of acute coronary events	IMCA	independent mental capacity advocate
GSF	gold standards framework	INR	international normalized ratio
		IOP	intraocular pressure

IPF	idiopathic pulmonary fibrosis	MEK	mitogen-activated protein kinase, also known as MAP2K
IS	ischaemic stroke	MFRA	multifactorial falls risk assessment
ISC	intermittent self-catheterisation	MG	myasthenia gravis
IU	international units	MGUS	monoclonal gammopathy of unknown significance
IV	intravenous	MHA	Mental Health Act
IVT	intravenous thrombolysis	MHC	major histocompatibility complex
IVU	intravenous urogram	MHRA	Medicines and Healthcare Products Regulatory Agency (UK)
JAK	Janus kinases, cytoplasmic tyrosine kinases and their genes	MI	myocardial infarction
JVP	jugular venous pressure	min	minute
KRT	kidney replacement therapy	MIND	a mental health charity in England and Wales
LA	local authority	MMSE	mini-mental state examination
LAA	left atrial appendage	MNA	mini-nutritional assessment
LABA	long-acting beta ₂ agonist	MND	motor neuron disease
LACI	lacunar infarct	MoCA	Montreal cognitive assessment
LAMA	long-acting muscarinic antagonist	MOVES	Trial of chondroitin and glucosamine for knee pain in osteoarthritis
LASI	longitudinal aging study in India	MPTP	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
LBBB	left bundle branch block	MRA	magnetic resonance angiography
LBD	Lewy body disease, an umbrella term including DLB and PDD	MRC	Medical Research Council
LCP	Liverpool care pathway for the dying patient	MRCPP	magnetic resonance cholangiopancreatography
LDH	lactate dehydrogenase	MRCPP	Membership of the Royal College of Physicians
LDL-C	low density lipoprotein cholesterol	MRgFUS	MRI-guided focused ultrasound
LE	life expectancy	MRI	magnetic resonance imaging
LED	levodopa equivalent dose	mRNA	messenger RNA
LFT	liver function test	MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
LGBTQ+	lesbian, gay, bisexual, transgender, queer plus other emerging gender and sexual identities	MS	multiple sclerosis
LH	luteinizing hormone	MSA	multiple system atrophy
LHRH	luteinizing hormone-releasing hormone	MSU	midstream urine
LMIC	low or middle income country	MT	mechanical thrombectomy
LMN	lower motor neuron	mtDNA	mitochondrial DNA
LMWH	low molecular weight heparin	mTOR	mammalian target of rapamycin: a serine/threonine protein kinase regulating cell growth and proliferation
LOAD	late-onset Alzheimer's disease	MTP	metatarso-phalangeal
LOC	loss of consciousness	MuSK	muscle specific tyrosine kinase
LP	lumbar puncture	MUST	malnutrition universal screening tool
LPA	lasting power of attorney	NA	noradrenaline
LPL	lymphoplasmacytic lymphoma	NABCOP	national audit of breast cancer in older patients
LPS	liberty protection safeguards	NAD +	nicotinamide adenine dinucleotide
LTOT	long-term oxygen therapy	NAFLD	non-alcoholic fatty liver disease, now known as MASLD
LUTS	lower urinary tract symptoms	NAIF	national audit of inpatient falls
LV	left ventricular	NaSSa	serotonin noradrenaline reuptake inhibitor
LVEF	left ventricular ejection fraction	NBM	nil by mouth
LVF	left ventricular failure	NCEPOD	National Confidential Enquiry into Patient Outcomes and Death
LVH	left ventricular hypertrophy	NCS	nerve conduction studies
LVO	large vessel occlusion	NCSE	non-convulsive status epilepticus
M ₁₋₅	muscarinic receptors	NELA	national emergency laparotomy audit
M band	monoclonal band	NF-kB	nuclear factor kappa light chain enhancer of activated B cells
Mab	monoclonal antibody	NG	nasogastric
MAO-A or B	monoamine oxidase A or B	NGO	non-governmental organisation
MAP	mean arterial pressure	NHS	National Health Service
MAP-K	mitogen-activated protein kinases: serine/threonine-specific protein kinases that relay signals from the cell surface to the nucleus	NHS CC	NHS continuing care
MAR	medicines administration record	NIA-AA	National Institute on Aging and the Alzheimer's Association (new criteria for diagnosis of AD)
MASD	moisture-associated skin damage	NICE	National Institute for Health and Care Excellence
MASLD	metabolic dysfunction-associated steatotic liver disease (replacing the term NAFLD)	NICs	national insurance contributions
MBBS	Bachelor of Medicine, Bachelor of Surgery (UK professional medical qualification)	NIH	National Institutes of Health (Agency of the US Dept. of Health)
MCA	Mental Capacity Act	NIHSS	National Institutes of Health stroke scale
MCA	middle cerebral artery	NIV	non-invasive ventilation
MCCD	Medical Certificate of Cause of Death	NKT	natural killer T cells
MCI	mild cognitive impairment	NMDA	N-methyl-D-aspartate, a receptor for glutamate
MCV	mean corpuscular volume	NMJ	neuromuscular-junction
MDRD	modification of diet in renal disease		
MDS	myelodysplastic syndrome		
MDT	multidisciplinary team		

NMS	neurally-mediated syncope	PMF	primary myelofibrosis
NNT	number needed to treat	PMR	polymyalgia rheumatica
NOF	neck of femur	POADR	prospective old age dependency ratio
NOGG	National Osteoporosis Guidelines Group	POAG	primary open angle glaucoma
NPH	normal pressure hydrocephalus	POCI	posterior circulation infarct
NSAID	non-steroidal anti-inflammatory drug	POP	plaster of Paris
NSCLC	non-small-cell lung cancer	POPS	perioperative medicine for older people having surgery
NSIP	non-specific interstitial pneumonia	PP	pulse pressure
NSTE-ACS	non-ST elevation acute coronary syndromes	PPAR γ	peroxisome-proliferator-activated receptor gamma
NSTEMI	non-ST elevation myocardial infarction	PPCs	postoperative pulmonary complications
NT-proBNP	N-terminal pro-B-type natriuretic peptide	PPI	proton pump inhibitor
NVH	non-visible haematuria	PPI	patient and public involvement
NYHA	New York Heart Association	PPO	potential prescribing omissions
O ₂	oxygen	PPS	post-polio syndrome
OA	osteoarthritis	PRISMA	a self-reported questionnaire for frailty
OADR	old age dependency ratio	PRISMS	potential of rtPA for ischemic strokes with mild symptoms trial
OD	once a day	PSA	prostate specific antigen
OECD	Organization for Economic Cooperation and Development	PSP	progressive supranuclear palsy
OGD	oesophago gastro duodenoscopy	PSR	potential support ratio
ONS	Office of National Statistics	PT (or physio.)	physiotherapy/ physiotherapist
OPG	osteoprotegerin	PTCA	percutaneous transluminal coronary angioplasty
ORBIT	acronym for a risk score for bleeding on anticoagulants for AF (older, renal impairment, bled before, iron low, taking antiplatelet drugs)	PTH	parathyroid hormone
OSA/HS	obstructive sleep apnoea/hyponoea syndrome	PTHrP	parathyroid hormone-related protein
OT	occupational therapy/ therapist	PUVA	psoralen + UVA treatment
OTC	over-the-counter (medicines)	PV	polycythaemia vera
P2Y12	purinergic receptors on platelets (bind clopidogrel family)	PVD	peripheral vascular disease
PA	pernicious anaemia	PVS	persistent vegetative state
PACG	primary angle closure glaucoma	QDS	four times a day
PACI	partial anterior circulation infarct	Qfracture	fracture risk tool advocated by SIGN and NICE
PAF	paroxysmal atrial fibrillation	QOF	quality and outcomes framework
PaO ₂	partial pressure of oxygen	QRISK3	UK cardiovascular risk calculator
PARP	poly ADP-ribose polymerase	QT	the time between the start of the Q wave and end of the T wave on an ECG
PBC	primary biliary cirrhosis	RA	rheumatoid arthritis
PCI	percutaneous coronary intervention	RA	right atrium
PCIS	posterior circulation ischaemic stroke	RAAS	renin angiotensin aldosterone system
PCR	polymerase chain reaction	RAGE/AGE	receptor for advanced glycation endproducts
PCS	posterior circulation stroke	RANKL	receptor activator of nuclear factor kappa-B ligand
PCT	primary care trust	RAS	renal artery stenosis
PD	Parkinson's disease	Ras	ras proto-oncogenes: GTPases that act as molecular switches in pathways for cell proliferation and survival
PD-1 inhibitor	programmed cell death protein 1 inhibitor (an immune checkpoint inhibitor)	RBBB	right bundle branch block
PDB	Paget's disease of the bone	RBC	red blood cell
PDD	Parkinson's disease dementia	RCC	renal cell cancer
PDE	phosphodiesterase	RCGP	Royal College of General Practitioners
PDK1	phosphoinositide-dependent kinase 1	RCP	Royal College of Physicians
PD-L1 inhibitor	programmed cell death ligand inhibitor	RCT	randomized controlled trial
PE	pulmonary embolism	RDW	red cell distribution width
PEC	percutaneous endoscopic colopexy	Rehab.	rehabilitation
PEFR	peak expiratory flow rate	REM	rapid eye movement
PEG	percutaneous endoscopic gastrostomy	RGSC	Registrar General's socio-economic class
PEG-J	percutaneous endoscopic gastrostomy with a jejunal extension	RLS	restless legs syndrome
PEJ	percutaneous endoscopic jejunostomy	RNA	ribonucleic acid
PET	positron-emission tomography	RNIB	Royal National Institute for Blind people
PHC	primary health centre (India)	ROS	reactive oxygen species
PICC	peripherally inserted central catheter	ROSIER	recognition of stroke in the emergency room scale
PICH	primary intracranial haemorrhage	RoSPA	Royal Society for the Prevention of Accidents
PIM	potentially inappropriate medication	RPE	retinal pigment epithelium
PIP	proximal interphalangeal	RS3PE	remitting seronegative symmetrical synovitis with pitting (o)edema
PIP2/3	phosphatidylinositol 4,5-bisphosphate and 3,4,5-trisphosphate (cell membrane phospholipids)	RSPCA	Royal Society for Prevention of Cruelty to Animals
PJ	slang for pyjama, as in pj paralysis	RTA	road traffic accident
PLMS	periodic limb movements in sleep	rt-PA	recombinant tissue-type plasminogen activator
PM	polymyositis	RUQ	right upper quadrant
		SA	sino-atrial

SABA	short-acting beta ₂ agonist	TENS	transcutaneous electrical nerve stimulation
SABR	stereotactic ablative radiotherapy	T _{FH}	T follicular helper cells
SAE	serious adverse event (with a medical product)	TFTs	thyroid function tests
SAH	subarachnoid haemorrhage	TGA	transient global amnesia
SAMA	short-acting muscarinic antagonist	TH	tyrosine hydroxylase
SaO ₂	arterial oxygen saturation	T _H	subset of T helper cells
SARI	serotonin antagonist-reuptake inhibitor	TIA	transient ischaemic attack
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2	TIBC	total iron binding capacity
SASP	senescence-associated secretory phenotype	TLOC	transient loss of consciousness
SBOT	short-burst oxygen therapy	TMJ	temporomandibular joint
SBP	systolic blood pressure	Tn	troponin
SC	subcutaneous	TNF α	tumour necrosis factor alpha
SCC	squamous-cell carcinoma	TOE	transoesophageal echocardiography
SCLC	small-cell lung cancer	tPA	tissue plasminogen activator
SCN	suprachiasmatic nucleus	TPN	total parenteral nutrition
SD	standard deviation	T _{reg}	regulatory T cells, a T helper subset with role in immune tolerance
SDH	subdural haematoma	TSH	thyroid stimulating hormone
SE	status epilepticus	tTG-IgA	tissue transglutaminase antibodies
sec	second	TTT	tilt-table testing
SERM	selective estrogen modulator	TUG	timed up and go test
Sestamibi or 'mibi' scan	technetium 99m methoxy isobutyl isonitrile scan	TUIP	transurethral incision of the prostate
sFLC	serum free light chain	TUMT	transurethral microwave therapy
SGLT2i	sodium-glucose co-transporter-2 inhibitor	TUNA	transurethral needle ablation
SIADH	syndrome of inappropriate antidiuretic hormone	TURBT	transurethral resection of bladder tumour
SIGN	Scottish intercollegiate guidelines network	TURP	transurethral resection of the prostate
SIRT	sirtuins: nicotine adenine dinucleotide-dependent histone deacetylases regulating critical signalling pathways	TVN	tissue viability nurse
SITS-MOST	safe implementation of treatments in stroke monitoring study	TVT	tension-free vaginal tape
SIVD	subcortical ischaemic vascular disease	U&Es	urea and electrolytes
SLE	systemic lupus erythematosus	UA	unstable angina
SLT	selective laser trabeculoplasty	UC	ulcerative colitis
SLT	speech and language therapist/ therapy	UCL	University College, London
SN	substantia nigra	UI	urinary incontinence
SNP	single nucleotide polymorphism (pronounced snip)	UIP	usual interstitial pneumonia
SNRI	serotonin and norepinephrine reuptake inhibitor	UK	United Kingdom
SNS	sympathetic nervous system	UKHSA	UK Health Security Agency
SOD	superoxide dismutase, an enzymatic antioxidant, which catalyses the dismutation of superoxide ions into oxygen and hydrogen peroxide	UKPDS	UK prospective diabetes study
SOL	space-occupying lesion	UMN	upper motor neuron
SPA	state pension age	UN	United Nations
SPECT	single-photon emission computerized tomography	UNHCR	UN High Commissioner for refugees
SPF	sun protection factor	UPR	unfolded protein response
SPLATT	acronym for falls assessment (symptoms, previous falls, location, activity, time, and trauma)	URTI	upper respiratory tract infection
SSNAP	sentinel stroke national audit programme	US	United States
SSRI	selective serotonin reuptake inhibitor	US\$	US dollar
Stat.	usually a one-off dose, given immediately, from the Latin statim	UTI	urinary-tract infection
STEMI	ST-elevation myocardial infarction	UV A and B	ultra violet light: A - longer wavelength associated with tanning and ageing, B - causes more sunburn
STOPP/START	screening tool of older persons prescriptions and screening tool to alert doctors to right treatment	V/Q	ventilation/perfusion
SVC	superior vena cava	VA	visual acuity
T1/T2 DM	type 1/type 2 diabetes mellitus	VAC	vacuum-assisted wound closure
T3	triiodothyronine	VaD	vascular dementia
T4	thyroxine	VAT	value added tax
TACI	total anterior circulation infarct	VATS	video-assisted thoracoscopic surgery
TAVI	transcatheter aortic valve insertion	VCSE	voluntary, community and social enterprise sector
TB	tuberculosis	VE	vaginal examination
TCC	transitional cell carcinoma	VEGF	vascular endothelial growth factor
tDCS	transcranial direct current stimulation	VGCC	voltage-gated calcium channels
TDP	transactive response DNA-binding protein	VO ₂ max	the maximum rate of oxygen the body can use during exercise
TDS	three times a day	VTE	venous thromboembolism
TEDS	thromboembolic deterrent stockings	WBC	white blood cell
		WCC	white cell count
		WHO	World Health Organisation
		YAG	yttrium aluminium garnet laser
		Z drugs	hypnotics in the zopiclone family
		ZIO	tradename of a biosensor to detect cardiac arrhythmias

About the companion website

This book is accompanied by a companion website:

www.wiley.com/go/lecturenotesgeriatricmedicine9e



The website includes:

- Key revision points for each chapter
- Appendix
- Extended content for specialty trainees
- Further reading

Global ageing

Introduction

The Western world turned grey in the 20th century, and the rest of the world is following this century at a more rapid pace.

In response to population ageing, the United Nations General Assembly declared 2021–2030 the Decade of Healthy Ageing and asked the WHO to lead on implementation, but the Coronavirus disease 2019 (COVID-19) pandemic has diverted attention.

The common afflictions of old age are now accepted, not as a cause for shame but as serious diseases. Films and novels portray various aspects of ageing. There is increasing discussion in mainstream media about dementia and its effects on individuals from all levels of society, including former heads of state, sporting, and literary figures. However, ageism is still an issue. In the developed world, experience of death is often limited to the deaths of very elderly parents, and there is a loss of familiarity with death as a natural process.

Changes in the global population

The world is affected by the four global demographic ‘megatrends’, all of which have implications for older people:

- 1 Population **growth**
- 2 Population **ageing**
- 3 International **migration**
- 4 **Urbanisation** (local migration)

Population growth

From antiquity, the world population increased gradually, with fluctuations due to factors including famine and pandemics, reaching one billion around 1800. Since then, the growth rate has been remarkable (see Figure 1.1).

Population growth is determined by the balance of birth and death rates.

In outline:

- Once childhood death rates start to fall, life expectancy (LE) increases.
- More people reach reproductive age, high birth rates continue, the median age of the population stays low, and the population grows rapidly.

- Birth rates then start to fall; the population continues to increase, but ages.
- Eventually, older people outnumber the young, and the population begins to fall.

This process is called demographic transition (see Figure 1.2).

Major drivers of the transition include improvements in food security, nutrition, housing, clean water and sanitation, income, education (especially for women), and public health measures such as immunisation and contraception. Medical interventions such as the management of cardiovascular risk factors and earlier detection and management of cancer have extended LE in later life.

World stages of transition in 2019 (Wang, Lancet 2020)

- 1 **Pre-transition:** no countries
- 2 **Early transition:** no countries (1970, 17 countries)
- 3 **Intermediate:** 35 countries
- 4 **Late transition:** 131 countries
- 5 **Post-demographic:** 38 countries, 18 with net emigration, and 20 with net immigration.

Population pyramids usually show the population divided into males and females in 5-year age bands. The shape shows the stage of transition, moving from expansive, a wide-based triangle where young children predominate, to a more rectangular shape as the population ages, constrictive as the base shrinks, and finally a rocket shape as there is little death until old age. The changing shape can be seen in the world population pyramids 70 years apart (see Figure 1.3).

The world population reached eight billion in 2022. The rate of world population growth has been slowing since the 1960s. Until recently, the UN estimated that the world population would peak at 11 billion in 2100, but the rapidity of the decline in fertility has exceeded predictions.

- Many women wish or need to work.
- Widespread television, mobile phones, and internet access have brought a quantum leap in access to information, education, and awareness of how others live.
- Aspirations for a higher standard of living and better opportunities for children may be factors driving the rapidity of change.

The latest modelling suggests that peak world population will occur sooner and will be falling by 2100 to 10.4 billion (UN 2022), a peak of 9.7 billion in 2065 with a fall to 8.8 billion by 2100 (Lancet 2020), or more optimistically, a peak of 8.6 billion in 2050 with a fall to 7 billion by 2100 (New Scientist 2023). See Figure 1.4.




Figure 1.1 World population from 10,000 BCE to 2019 (BCE is before the common era, CE is the common era, previously AD or anno domini). The arrow shows the impact of the Black Death. Source: Adapted from Our World in Data.




Figure 1.2 Demographic transition. Source: Our World in Data / CC BY - 4.0.

Population ageing

As discussed earlier, populations tend to age as they grow.

Population ageing has four key characteristics (UN 2009). It is:

- 1 **Unprecedented**, without parallel in the history of humanity.
- 2 **Pervasive**, affecting nearly all the countries in the world. Better treatment for HIV has enabled LE in sub-Saharan Africa to increase following a dip. Civil wars still have an impact on affected areas. It is too early to assess the overall effect of the COVID pandemic, but LE dipped for the first time in decades in many countries.
- 3 **Profound**, with major consequences and implications for all aspects of life.
- 4 **Enduring**, as short of a worldwide disaster, the trend will not be reversed.

Ways of expressing the age of a population


Median age

- Age at which half of the population is older and half is younger.
- It enables a single figure to compare countries and measure change.


World median age: 22.6 years in 1960, 30.9 in 2020, projected 36.2 in 2050.

Population over a specified age

- The age at which populations are considered 'elderly' is over 65 years in many statistics.
- Some data sets categorise people of 60+ as older and people of 80+ as the 'oldest old'.



© 2022 United Nations, DESA, Population Division. Licensed under Creative Commons license CC BY 3.0 IGO.
 United Nations, DESA, Population Division, *World Population Prospects 2022*, <http://population.un.org/wpp/>



© 2022 United Nations, DESA, Population Division. Licensed under Creative Commons license CC BY 3.0 IGO.
 United Nations, DESA, Population Division, *World Population Prospects 2022*, <http://population.un.org/wpp/>

Figure 1.3 World population pyramids for 1952 and 2022. Source: United Nations (UN) World population prospects 2024 / CC BY 3.0.

Global population size: estimates, 1950–2022, and medium scenario with 95 per cent prediction intervals and high- and low-fertility scenarios, 2022–2100





Figure 1.4 Global population and projections
Source: UN World population prospects summary, 2022 / CC BY 3.0.

Population by age group, including UN projections, World

Historic estimates from 1950 to 2021, and projected to 2100 based on the UN medium-fertility scenario. This is shown for various age brackets and the total population.



Source: United Nations, World Population Prospects (2022)

OurWorldInData.org/world-population-growth • CC BY

Figure 1.5 The changing proportions of different age bands within the global population. Source: Modified from Our World in Data / CC BY 4.0.

The proportion of the world population aged 65+ was 5% in 1960, 10% in 2022, and predicted to rise to 16% in 2050. For the first time in world history, in 2018, people aged 65+ outnumbered children under 5 (see Figure 1.5).

Within the older population, the number of people aged 80+ will increase markedly (see Figure 1.6). This has implications for health and social services, as this age group has more needs. This will occur in middle-income countries as well as high-income countries.

Life expectancy at birth

Prior to 1800, global LE at birth is estimated to have been between 20 and 30. Extremely high infant and child mortality was the major factor, but people have always lived into middle and older age, just a much smaller proportion than today. In the absence of data, inferences about ageing can be made from artistic artefacts, e.g. figurines, drawings, and contemporary texts. In the 7th century BCE, the Greek poet Hesiod wrote





Figure 1.6 Projected world population aged 80 and over. *Source:* UN World population prospects 2024 / CC BY 3.0.

Life expectancy, 1543 to 2021



Source: UN WPP (2022); Zijdeman et al. (2015); Riley (2005)

OurWorldInData.org/life-expectancy • CC BY

Note: Shown is the 'period life expectancy'. This is the average number of years a newborn would live if age-specific mortality rates in the current year were to stay the same throughout its life.

Figure 1.7 The changing life expectancy at birth in the UK and Sweden over several centuries. *Source:* Modified from Our World in Data / CC BY 4.0.

that a man should marry at 'not much less than 30, and not much more'. To be a consul in ancient Rome, you had to be 43 – 8 years older than the minimum age of 35 to hold the presidency of the US. In the 1st century, Pliny records a few individuals with well-documented life spans of over 100 years, including Cicero's wife Terentia (103 years).

- Data about LE in populations is available for the UK from 1543 and Sweden from 1750.
- In 1800, more countries began collecting data, but global data, compiled by the UN, has only been available since 1948 (see Figure 1.7).
- Before 1800, no country had a sustained LE at birth over 40 years.
- Global inequality increased after 1850 as LE began to increase in parts of Europe and widened in 1900 as LE also increased in Australia and the US. By 1950, Norway had a LE of 72 years; the mean across Africa was 36 years, and in Mali, only 26 years.




Figure 1.8 Life expectancy in a wider range of countries showing convergence. *Source:* Modified from Our World in Data / CC BY 4.0.

- From the 1950s, LE in most regions increased at a comparable rate until the HIV epidemic, which peaked in sub-Saharan Africa in the 1980s–1990s, caused a marked fall there.
- Since 2000, LE has again increased in all regions, with a faster trajectory in Africa, so the global gap is narrowing (see Figure 1.8).
- The average world citizen born in 1950 could expect to live to 46 years, to 66 by 2000, and to 73 in 2019, with a projection of 77 years by 2050.
- Since 2020, COVID has caused LE to fall. Data on the extent is incomplete, but there has been a fall of almost 3 years in the US, and the dip is now visible in world data.

To visualise the increase in LE since records became available, look at the interactive site in Our World in Data: life expectancy-increased-in-all-countries-of-the-world.

Life expectancy at age 65

Life expectancy at age 65 is the average number of additional years of life a 65-year-old person would live if subjected to the age-specific mortality risks of a given period for the rest of their life.

- Worldwide, a person reaching 65 years old in 2020 can expect to live an additional 17 years, increasing to 19 years by 2050.
- Australia and New Zealand currently have the highest LE at age 65 (21 years), followed by Europe and Northern America (19 years).
- Life expectancy at age 65 is projected to increase in all regions, but with the smallest gain in sub-Saharan Africa.

Estimating years spent in health

There is now more focus on whether the extra years of life are spent in health. There are several similar metrics with different definitions, so to compare data, e.g. across countries, use the same metric.

Health-adjusted life expectancy (HALE), used by the WHO, is the expected number of remaining years of life spent in good health, i.e. without irreversible limitations in activities of daily living, from birth

or age 65, assuming current rates of mortality and morbidity. Health status is derived from health statistics. In the EU, the Healthy Life Years indicator (HLY) is also known as disability-free life expectancy (DFLE) and uses self-reported data on disability. The UK metric of Healthy Life Expectancy (HLE) is not synonymous with DFLE, as it asks about the perception of health rather than disability.

Across the world, people live longer and live more years in good health. Between 2000 and 2019:

- LE at birth increased from 66.8 to 73.3 years.
- HALE increased from 58.3 to 63.7 years.
- LE and HALE are consistently higher for females.

Within individual countries, there are socio-economic gradients for LE and HALE.

Old-age dependency ratio

The old-age dependency ratio (OADR), the number of old-age dependents (people aged 65+) per 100 persons of working age (aged 20 to 64 years), is used to compare the economic prospects of countries related to their ageing population (see Figure 1.9).

In 2020:

- Japan tops the list and will continue to do so in 2050.
- Most countries with high OADRs are European; more Asian countries will be among this group by 2050.

Some data still uses 15–64 as 'working age', but the age of 20 reflects longer education and later entry into the work force. The use of 'age 64' will also become outdated as older people choose or need to defer retirement.

Whatever age bands are used, a more intuitive way of expressing the number of working people available to support older people is the Potential Support Ratio (PSR), i.e. the inverse of OADR. Using data for people aged 25–64 per person aged 65+; in 2019, Japan had a ratio of 1.8,

Economic old-age dependency ratios, world and regions, estimates for 1990–2021 and projections for 2022–2050




Figure 1.9 OADRs calculated from numbers of people aged 65+ per 100 persons aged 20–64. Source: UN World social report 2023 / CC BY 3.0.

the lowest in the world. A further 29 countries, mostly in Europe and the Caribbean, already have PSRs below 3.

Prospective old-age dependency ratio

As LE increases and older people stay economically active, rather than defining people as ‘old’ at an arbitrary age, newer metrics are being used. The prospective old-age dependency ratio (POADR) is calculated as the number of persons above the age closest to a remaining LE of 15 years compared to the number of persons between age 20 and that age.

Sex ratios and the age-sex gap

Unless there is intervention, more male infants are born than females in all populations (105:100). However, boy babies have higher perinatal and infant mortality. For data and discussion on sex ratios in different countries, see Our World in Data.

In antiquity, men were said to outlive women. This may have been true, but it may be a reporting phenomenon as most cultures recorded more information about men. Once comprehensive data became available, it was clear that, on average, women outlived men. The difference results from a complex interaction between biological, behavioural, and socio-economic factors that is uneven throughout the lifespan (e.g. due to the risks of childbirth, attitude to risk, military service and dangerous jobs, and cardiovascular disease). The size of the difference has varied historically.

- By 2020, it was universal that women live longer than men, although the difference ranges from less than a year in Nigeria to over 10 years in Russia (the global average is 4.8 years).
- 90% of supercentenarians (people reaching 110 years of age or older) are women.
- Thus, in many countries, particularly those with older populations, women outnumber men.

Countries where most older people live

India overtook China as the world’s most populous country in April 2023. It is likely that between 2060 and 2070, sub-Saharan Africa will become the most populous region in the world.

The proportion of older people varies greatly from country to country, but as countries undergo demographic transition, the differences are diminishing. Globally, there were 703 million people aged 65+ in 2019. The region of Eastern and South-Eastern Asia was home to the largest number of older people (261 million), followed by Europe and Northern America (over 200 million).

Data from a range of countries are shown in Table 1.1.

Japan’s population is the oldest in the world; most European countries have median ages around 43 years, but population ageing is not restricted to the developed world. In 2019:

- Nearly one in four people aged 65+ lived in China.
- Five countries (China, India, the US, Japan, and the Russian Federation) accounted for half of the world’s population aged 65+.
- Five countries (China, the US, India, Japan, and Germany) were home to half of people aged 80+.

Table 1.1 Percentage of people aged 65+ and median age in 2019 (Our World in Data).

	% aged 65+	Median age years	World population ranking	Number of people aged 65+ (million)
Japan	28	46.7	11	35.6
Italy	23	45.7	23	14.0
UK	19	40.1	21	12.5
US	16	37.7	3	53.3
Russian Fed	15	39.4	9	22.0
China	12	37.0	1 (2 from 2023)	164.5
Brazil	9	33.5	6	19.3
Mexico	7	29.2	10	9.5
India	6	28.4	2 (1 from 2023)	87.1
Indonesia	6	29.7	4	16.3
Nigeria	3	18.1	7	5.5
WORLD	9	30.7	7.7 billion	702.9

Over the next three decades, the number of people aged 65+ is projected to more than double, reaching more than 1.6 billion people in 2050.

All regions will see an increase in the 65+ population between 2019 and 2050.

- The largest increase (312 million) is projected to occur in Eastern and South-Eastern Asia.
- The fastest increase (226%) is expected in Northern Africa and Western Asia.
- The second fastest increase (218%) is projected for sub-Saharan Africa.
- The increase is expected to be relatively small in Australia and New Zealand (84%) and in Europe and Northern America (48%), where the population is already older.

An excellent resource to look at demographic changes in individual countries is Our World in Data – the trends with time, effects of war (e.g. France 1918, 1944; Japan 1945), earlier flu pandemics, and HIV (e.g. Eswatini) are readily seen.

The pace of population ageing

The pace of population ageing is accelerating. It took 115 years (1865–1980) for the proportion of older people to double in France (from 7 to 14%), whilst in China the proportion will have doubled between 2000 and 2026. This gives countries very little time to adjust.

International migration

International migration is increasingly important.

- The number of people living outside their country of birth or citizenship reached 281 million in 2020, up from 173 million in 2000.
- The rate is continuing to increase due to economic migration and people fleeing war and persecution.

Most economic migrants are of working age and move to developed countries with older populations, so the countries they leave ‘age’ and the age in the destination country falls (e.g. Sweden). Immigration has an immediate impact on population age and growth in countries where natural population growth has fallen; in half of these 38 countries, immigration has ensured stable or rising populations.

However, emigration may worsen natural population decline, such as in Romania, where waves of immigration and emigration have caused marked fluctuations (see Figure 1.10).

The effect on populations of rapid, massive migration due to war depends on the situation, but typically more women and children are displaced. It is too early to evaluate the effect of the Russian invasion of Ukraine in 2022, but over 2 million refugees fled the fighting in the first 2 weeks. For context, United Nations High Commissioner for Refugees (UNHCR) estimates that there were 43.4 million refugees globally in 2023.

Urbanisation

The other major change affecting populations is urbanisation. The UN estimates that in 2007, for the first time in human history, the number of people in urban areas overtook the number in rural settings (see Figure 1.11). As with international migration, it is mainly younger people who leave the countryside, fragmenting families and altering the age distribution of areas within a country. Conflicts also cause massive internal displacements in countries.

Typical patterns of health and social care

More developed countries

Demographic changes

- Death, which was common in infancy and usual before 65 years, is now rare in infancy and unusual before 65 years.
- Life expectancy has generally continued to rise, but the rate of increase has flattened since 2010 in the US, Canada, Australia, the UK, and several European countries. By contrast, in Japan, a period of low gains in LE was followed by a return to faster improvement.
- Life expectancies have dipped because of the direct and indirect effects of COVID, but it is still too soon to be sure of the size and duration of this effect.
- The dramatic rise in the older population over the past 100 years is now slowing.
- The number of ‘very old’, i.e. those ≥ 80 years of age, is still increasing rapidly.
- Ageing populations are associated with slower economic growth due to lower productivity, less innovation and a risk of ‘ageing recessions’ due to labour shortages plus increased demands for care. In 2010, China overtook Japan as the world’s second-largest economy, due in part to the ageing and shrinking population of Japan.

Medical services


- Sophisticated health systems are set up with specialised services for elderly people.
- An older person costs health services nine times as much as a young person.
- Population ageing requires increased health funding, estimated in the EU at 0.6% per year between 2015 and 2050, so price growth and technological advancements will be the main contributors to future growth in health care expenditure.
- Most deaths are due to cardiovascular disease, dementia, and cancer (see Figure 1.12).
- Time-to-death, particularly the final year of life, rather than age, is a stronger driver of healthcare expenditure, and there is an inverse relationship between age and the cost of end-of-life care.
- Rising expectations of older people and their carers also fuel rising health costs.
- Ethical dilemmas will become more pressing, e.g. the prolongation of death by technological intervention and the debate about access to euthanasia.
- Medical training continues to value increasing specialisation, so practitioners struggle to deal with complex aetiologies (sociological, psychological, and medical), multiple pathology and the frailty and atypical presentations common in older patients. This can result in a mismatch between the aspirations of young medics and the needs of their older patients.

Community services

- The provision of community care is more varied than for acute care. Inter-country comparisons are complex because of political, socio-economic, and demographic differences. The most straightforward comparison is the proportion of people in care homes; there used to be marked variation, but figures are converging to 4–7% of those aged 65+.

Population growth rate with and without migration, Sweden

The annual change in population with migration included, versus the change if there was zero migration (neither emigration or immigration). The latter therefore represents the change in population based solely on domestic births and deaths.




Source: United Nations, World Population Prospects (2022)

OurWorldInData.org/world-population-growth • CC BY

Population growth rate with and without migration, Romania

The annual change in population with migration included, versus the change if there was zero migration (neither emigration or immigration). The latter therefore represents the change in population based solely on domestic births and deaths.




Source: United Nations, World Population Prospects (2022)

OurWorldInData.org/world-population-growth • CC BY

Figure 1.10 Population growth with and without migration: in Sweden, where migration is increasing the population, and in Romania, where it has decreased the population. Source: Our World in Data / CC BY 4.0.


- The development of patterns of care is similar. Historically, there was a heavy reliance on self-sufficiency and family care. The healthy and wealthy elderly have always fared the best. The more disadvantaged have always needed support from others.
- In the 'Old World,' non-family support was provided by the church or by occupationally related charities or guilds. In England, the state began to take a more active role after the dissolution of the monasteries with the first Poor Law Act of 1601, which provided workhouse care and 'outdoor relief.' This continued until the end of the 19th century. The 20th century saw the beginning of the welfare state – gradually growing in the first half of the century, reaching a peak mid-century, and then declining towards the end of the 1980s. State provision of services was replaced by state regulation of services provided by other organisations. This regulation was gradually devolved and often weakened.
- From the 1980s on, nursing homes in the US, Europe, and Australia were increasingly run for profit, now mainly by multinational companies.
- Detailed case studies (2021) describe the provision and financing of long-term care (facility-based health care, home-based care, residential care, and personal care) in Australia, several European countries, Japan, the Republic of Korea, and the US. Common themes are issues with eligibility, equity, quality, affordability, and funding streams.
- Care for people with dementia is a major issue.



Source: World Bank based on data from the UN Population Division
 OurWorldInData.org/urbanization • CC BY
 Note: Urban populations are defined based on the definition of urban areas by national statistical offices.

Figure 1.11 Most people now live in urban areas.
 Source: Our World in Data / CC BY 4.0.

Leading causes of death in high-income countries



Source: WHO Global Health Estimates. Note: World Bank 2020 income classification.

Figure 1.12 Top ten causes of death in high-income countries.
 Source: WHO Global Health Estimates.

Less developed countries

Demographic changes

- Once people reach old age in developing countries, their LE is not much lower than in the developed world (Table 1.2).
- Until recently, the proportion of older people was low, but as countries such as China and India are so populous, over 60% of the world's elderly population already lives in these countries.
- These countries' population structures are changing rapidly with falling birth rates as contraceptive policies become effective (or are imposed), infant mortality is reduced, and survival in adult life improves.
- European studies show that babies with low birth weight and reduced growth in the first year have poor adult health, e.g. with hypertension

Table 1.2 Mean life expectancy at different ages (UN 2019).

Country	At birth	At 60years	At 80years
World	73.3	21.1	8.2
Low-income	65.1	17.4	5.9
Lower-middle income	69.4	18.6	6.8
Higher-middle income	76.3	21.2	7.7
High income	80.9	24.3	9.8


and hyperglycaemia. This is likely to have significant consequences in India and Southeast Asia.

- Potentially preventable congenital and childhood disabilities will complicate old age.
- Poor people will be unable to get sufficient wealth to provide for themselves in old age, so the total burden will either fall on the state or older people will be neglected.
- Governments have many competing financial demands, e.g. education, housing, and the development of infrastructure.
- Many countries struggle with debt, and political instability is common.
- Population patterns are at risk of distortion by epidemics, e.g. HIV/AIDS, civil war, and migration, e.g. sub-Saharan Africa.

Medical services

- Communicable diseases still claim most lives, but cardiovascular disease is increasing (see Figure 1.13).
- Health services are often primitive, patchy, and inappropriate for needs with huge urban/rural divides.
- There may be conflict between traditional healers and scientific approaches.
- The state may pursue 'high-tech' for the few over public health measures that would help many.
- Private health care clinics grow rapidly in cities, regulation may be limited, and people may shop around until they get an opinion that they like.

Leading causes of death in low-income countries



Source: WHO Global Health Estimates. Note: World Bank 2020 income classification.

Figure 1.13 Top ten causes of death in low-income countries. Source: WHO Global Health Estimates.

- There is often limited access to therapies and equipment for rehabilitation.
- Doctors and nurses need training in geriatrics because of worldwide demographic change.
- Development may be restricted by the tight macro-economic practices enforced by the International Monetary Fund, which encourage privatisation and limit a government's ability to invest in public health.
- Globalisation via the World Trade Organisation has resulted in conflict over the cost of drugs. Unaffordable prices for patented drugs ensure financial profits for Pharma, enabling the development of new drugs, but developing countries need access to cheap generic drugs, e.g. for hypertension, diabetes, and HIV. Efforts to distribute COVID vaccines worldwide and limited countries of manufacture highlighted the difficulties.
- World trade tends to promote bad health habits, e.g. smoking, high sugar intake, excess alcohol, and recreational drug abuse.

Community services

- Most of the population continues to work for as long as they are able, and when they cannot, they must rely on family support; retirement, at least for most people, is a concept of the developed world.

Ageing in India in 2023

Demographic changes

India is in a rapid phase of transition. Life expectancy at birth has been increasing since the 1950s, with a recent dip due to COVID (see Figure 1.14). Of note, male LE was longer than that of females until 1980. As the birth rate is higher in India than in China, India became the most populous country in 2023.

- The population of India is around 1.5 billion people (UN data).
- India has 17.8% of the world's population.
- The median age in India is 28.7 years.
- Fertility has fallen from 5.9 children per woman in 1965 to 2.1 in 2020.
- The number of children under the age of five peaked in 2007.
- The population growth rate has been falling since 1983.
- Urbanisation has increased from 20% in 1970 to 35% in 2020.
- About half a million people emigrate every year.

The fall in the numbers of children means that the base of the population pyramid is becoming progressively constricted (see Figure 1.15) and young adults are the largest group.

Life expectancy at the age of 65 and older in India has also increased for both men and women since 1955, and as a result, India's elderly population is growing rapidly (Table 1.3).

Between 1970 and 2020, the number of children aged 0–14 increased, plateaued and has been falling since 2010. The population age 15–64 has increased steadily by threefold; the over-65s have gone up over fourfold; and the over-80s, sevenfold, although they still make up only 7% and 1% of the population, respectively (see Figure 1.16).

Causes of death and disability

Indian states are in different phases of epidemiological transition, and there are large variations in disease burden across the states. People are living longer, but in 2019, only a fifth of registered deaths in India had a medically certified cause of death, so causes of death are based on extrapolation.

India generates considerable data on health aspects, but the data are fragmented and non-standardised, and there is little quality control. The Ayushman Bharat Digital Mission developed a system to generate a unique health identification number for every individual for use across a range of healthcare providers (to document cases of COVID and vaccinations), but the use of this number is still optional.

- Communicable diseases have fallen.
 - Polio has been eliminated, but malaria, tuberculosis, leprosy, AIDS, and a swathe of 'neglected tropical diseases' are still significant (see Figure 1.17).
 - Mortality from TB has halved since 1990 to 23 per 100,000, but India still has a quarter of the world's cases, an estimated 28 million new cases in 2018.
 - 1.47 million of these are drug-resistant TB, a situation local sources believe has arisen because of 'unregulated treatment by private providers.'
- The prevalence of noncommunicable diseases is rising steadily as the population ages.
 - Tobacco and alcohol use, a lack of exercise, and a poor diet have resulted in a high prevalence of metabolic syndrome and hypertension. Death rates from ischaemic heart disease (IHD), stroke, diabetes, and cancer are increasing.
 - Although domestic air pollution has fallen with cleaner cooking, poor air quality contributes to chronic obstructive pulmonary disease (COPD).
 - Malnutrition is still widespread. The 2019 Global Hunger Index ranks India at 102 out of 117 countries assessed and accounts for over two-thirds of deaths under 5 years old. The sequelae in the survivors will include poor health in middle and older age.
 - Injuries are another significant cause of mortality and morbidity.




Figure 1.14 Life expectancy in India is now higher in women than men. The dip after 2019 was due to COVID. Source: UN World population prospects 2024 / CC BY 3.0.